Comparative Computational Study of SARS-CoV-2 Receptors Antagonists from Already Approved Drugs

15 April 2020, Version 3
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

According to the World Health Organisation, on April 12, 2020, the number of confirmed cases of COVID-19 has already exceeded an estimate of 1 600 000 and 105 000 deaths worldwide. Given this, the impact of COVID-19 on humanity cannot be overlooked, and basic research are urgently needed. This research aims to find antagonists already approved for another diseases, that may inhibit activity of the main protease (Mpro) of the SARS-CoV-2 virus, as well as modulate the ACE2 receptors, largely found in lung cells and reduce viral replication by inhibiting NSP12 RNA Polymerase. Docking molecular simulations were realized among a total of 28 ligands published in the literature against COVID-19. Docking studies were made with algorithm of AutoDock Vina 1.1.2 software. A structure-based virtual screening was performed with MTiOpenScreen. Subsequently, the physical-chemical and pharmacokinetic parameters were analyzed with SwissADME in order to select only the most promising ones. Finally, simulations of molecular dynamics with elapsed time of 4 nanoseconds (ns) were analysed in order to better understand the action of drugs to the detriment of the limitations of molecular docking. This work has shown that, in comparative terms, simeprevir, paritaprevir and elbasvir are currently among the most theoretical promising drugs in remission of symptoms from the disease. An important structure that has already been reported in preclinical and clinical studies, in which theoretical results also corroborates high modulation in viral receptors is: indinavir. The second group of promising drugs includes remdesivir, baricitinib and azithromycin, which also have clinical tests. Apparently, the repurposing drugs (hydroxy)chloroquine and chloroquine were not showed effective, as monotherapies, against SARS-CoV-2 virus or ACE2 receptors found predominantly in pneumocytes. Meanwhile, it has not been able to reach conclusive results due to the limitations of computational techniques that do not take into account numerous empirical parameters.

Keywords

SARS-CoV-2
ACE2 antagonists
Remdesivir
Molecular Docking
Molecular Dynamics
Virtual Screening
ADME

Supplementary materials

Title
Description
Actions
Title
virtual screening
Description
Actions

Supplementary weblinks

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.